

## Supplemental Data

### **Human CRY1 variants associate with attention deficit/hyperactivity disorder**

O. Emre Onat<sup>1</sup>, M. Ece Kars<sup>1</sup>, Şeref Gül<sup>2</sup>, Kaya Bilguvar<sup>3</sup>, Yiming Wu<sup>4</sup>, Ayşe Özhan<sup>1</sup>, Cihan Aydın<sup>2</sup>, A. Nazlı Başak<sup>5</sup>, M. Allegra Trusso<sup>6</sup>, Arianna Goracci<sup>6</sup>, Chiara Fallerini<sup>7</sup>, Alessandra Renieri<sup>7,8</sup>, Jean-Laurent Casanova<sup>9,10,11,12,13</sup>, Yuval Itan<sup>4,14</sup>, Cem E. Atbaşoğlu<sup>15</sup>, Meram C. Saka<sup>15</sup>, İ. Halil Kavaklı<sup>2</sup> and Tayfun Özçelik<sup>1,16,17</sup>

Correspondence to: [tozcelik@bilkent.edu.tr](mailto:tozcelik@bilkent.edu.tr)

#### **This PDF file includes:**


Supplemental Figures 1 & 2

Captions for Supplemental Tables 1 to 14


Supplemental Tables 15 to 24

#### **Other Supplementary Materials for this manuscript include the following:**

Supplemental Tables 1 to 14 (single Excel file)



18  
 19 **Supplemental Figure 1. Kinship, sex-determination and principal component analysis of the 447-**  
 20 **individual validation cohort.** Reported relationships and gender are illustrated by different colors. (A)  
 21 Proportion of SNPs with identical-by-state zero (IBS0) against estimated kinship coefficient from the  
 22 SNP data using KING software, (B) number of Y-Chr SNPs against X-Chr heterozygosity are plotted. (C)  
 23 Principal component analysis projected along the PC1 and PC2 axes.



24

25 **Supplemental Figure 2. *CRY1* c.1657+3A>C genotyping by PCR and Hpy188I restriction enzyme**  
 26 **digestion.** Heterozygotes for the c.1657+3A>C mutation yielded 3 fragments of 623 bp + 347 bp + 276  
 27 bp. In homozygous individuals the 623 bp product was completely digested. Positive and negative  
 28 controls were included in each amplification and digestion reaction.

29

30 **SUPPLEMENTAL TABLES** (please see xlsx document for Supplemental Tables 1-14)

31 **Supplemental Table 1.** DSM-5 ADHD, ASRS scores and demographics of the 14-family  
32 discovery cohort (genotype denotes CRY1Δ11 status).

33 **Supplemental Table 2.** DSM-5 ADHD & ASRS symptoms of the 14-family discovery cohort.

34 **Supplemental Table 3.** Sleep behavior of 12 families from the 14-family discovery cohort.  
35 Families DSPD-1, -4, -6, -9 have been partially reported and families -7, -14 fully reported  
36 elsewhere (ref. 1); genotype denotes CRY1Δ11 status.

37 **Supplemental Table 4.** Comorbidities in the 14-family discovery cohort (genotype denotes  
38 CRY1Δ11 status).

39 **Supplemental Table 5.** ADHD severity and sunlight exposure times in the 14-family discovery  
40 cohort (genotype denotes CRY1Δ11 status).

41 **Supplemental Table 6.** DSM5 ADHD & ASRS scores, and sleep behavior of the 447-individual  
42 whole exome sequenced validation cohort (genotype denotes CRY1Δ11 status).

43 **Supplemental Table 7.** Gene-based prioritization using SKAT-O test of the 447-individual  
44 whole exome sequenced validation cohort.

45 **Supplemental Table 8.** CRY1Δ11 (rs184039278) allele frequencies in different populations.

46 **Supplemental Table 9.** Association of CRY1Δ11 with the BioMe™ BioBank phenotypes after  
47 filtering.

48 **Supplemental Table 10.** BioMe™ BioBank filtered phenotypes.

49 **Supplemental Table 11.** BioMe™ BioBank phenotypes of the CRY1Δ11 carriers.

50 **Supplemental Table 12.** Coding, rare and deleterious variations of core clock (CRY1, CRY2,  
51 PER1, PER2, PER3, ARNTL, CLOCK and CSNK1D) and additional candidate clock genes

52 (CSNK1E, ARNTL2, FBXL3, FBXL21, BHLHE40, BHLHE41, NR1D1 and RORA) that were  
53 identified by whole exome sequencing in the 447-individual validation cohort.

54 **Supplemental Table 13.** DSM5 ADHD & ASRS scores, and sleep behavior of family DSPD-36  
55 with CRY1Δ6.

56 **Supplemental Table 14.** HADDOCK results.

57 **Supplemental Table 15.** ADHD and DSPD phenotypes of the 447-individual validation cohort.

|              | <b>DSPD+</b> | <b>DSPD-</b> | <b>Total</b> |
|--------------|--------------|--------------|--------------|
| <b>ADHD+</b> | 62           | 16           | 78           |
| <b>ADHD-</b> | 123          | 246          | 369          |
| <b>Total</b> | 185          | 262          | 447          |

58

59 **Supplemental Table 16.** Filtering criteria for variant discovery.

|  | <b>Dominant mutations</b>  | <b>Recessive mutations</b> |
|--|--|----------------------------|
| <b>MQ</b> (mapping quality)  | < 20   | < 20                       |
| <b>VQSR</b> (variant quality score recalibration)                                | Except "PASS" and "."  | Except "PASS" and "."      |
| <b>Q</b> (Phred quality score)   | < 30   | < 30                       |
| <b>FS</b> (Fisher's strand)  | > 60   | none                       |
| <b>SOR</b> (strand odds ratio)   | > 3.0  | none                       |
| <b>MQRankSum</b>   | < -12.5  | none                       |
| <b>ReadPosRankSum</b>  | < -8.0   | none                       |
| <b>QD</b> (qual by depth)  | < 2.0  | none                       |
| <b>MAF big databases:</b><br>GnomAD (n138,632), ExAC (n60,706), KaviAR (n77,781) | ≤ 0.005  | ≤ 0.05                     |
| <b>MAF additional databases:</b><br>1000g (n2,504), EVS (n6,503)                 | ≤ 0.005  | ≤ 0.05                     |
| <b>MAF Turkish cohorts:</b><br>In-house: exome_seq (n2,671)/genome_seq (n703)    | ≤ 0.01   | none                       |
| <b>Functional annotation</b><br>(selected for further analysis)                  | <b>LoF</b> (splice-site, frameshift indel, stop-gain, stop- & start-loss)<br><b>Missense</b> with MetaSVM "D" and CADDphred ≥ 25.0<br><b>Start-gain and inframe indels</b> with CADDphred ≥ 20.0<br><b>Non-essential splice-site</b> (±3 bp) with dbscSNV-ADA & dbscSNV-RF < 0.6, Spidex < 5.0 |                            |
| <b>Low complexity region variants</b>  | excluded   |                            |

60

61 **Supplemental Table 17.** Summary of core and candidate clock gene variants.

| Gene                         | Annotation             | HGVS.c         | HGVS.p       | Affected Hom/Het | Unaffected Hom/Het | MAF-TR   |
|------------------------------|------------------------|----------------|--------------|------------------|--------------------|----------|
| <b>Core clock genes</b>      |                        |                |              |                  |                    |          |
| CRY1                         | splice_donor           | c.825+1G>A     | -            | 0/1              | 0/0                | 0        |
|                              | splice_donor           | c.1657+3A>C    | -            | 0/9              | 0/0                | 8.06E-03 |
| PER1                         | splice_donor           | c.3072+3G>A    | -            | 0/0              | 0/2                | 3.10E-04 |
|                              | splice_acceptor        | c.104-4_-3dup  | -            | 0/1              | 0/0                | 0        |
| PER2                         | inframe_deletion       | c.2910_2936del | p.971_979del | 0/0              | 0/1                | 0        |
| CRY2                         | no variant             | -              | -            | -                | -                  | -        |
| PER3                         | no variant             | -              | -            | -                | -                  | -        |
| ARNTL                        | no variant             | -              | -            | -                | -                  | -        |
| CLOCK                        | no variant             | -              | -            | -                | -                  | -        |
| CSNK1D                       | no variant             | -              | -            | -                | -                  | -        |
| <b>Candidate clock genes</b> |                        |                |              |                  |                    |          |
| CSNK1E                       | structural_interaction | c.108C>A       | -            | 0/0              | 0/1                | 6.20E-04 |
|                              | missense               | c.736A>G       | p.Met246Val  | 0/0              | 0/3                | 1.55E-03 |
| FBXL3                        | structural_interaction | c.978T>C       | -            | 0/1              | 0/0                | 0        |
| BHLHE40                      | missense               | c.673C>T       | p.Arg225Trp  | 0/1              | 0/0                | 0        |
| BHLHE41                      | inframe_insertion      | c.1212_1214dup | p.Ala405dup  | 0/1              | 0/0                | 0        |
|                              | inframe_deletion       | c.1197_1205del | p.400_402del | 0/0              | 0/1                | 1.24E-03 |
|                              | inframe_deletion       | c.900_902del   | p.Ala301del  | 0/0              | 0/2                | 0        |
|                              | frameshift             | c.877_902del   | p.Pro293fs   | 0/0              | 0/1                | 0        |
|                              | inframe_deletion       | c.1215_1229del | p.406_410del | 0/1              | 0/0                | 0        |
|                              | inframe_deletion       | c.1230_1232del | p.Ala411del  | 0/4              | 0/5                | 3.10E-03 |
|                              | inframe_deletion       | c.1215_1232del | p.406_411del | 0/1              | 0/0                | 6.20E-04 |
|                              | inframe_insertion      | c.1212_1214dup | p.Ala405dup  | 0/1              | 0/0                | 0        |
|                              | inframe_insertion      | c.1227_1232dup | p.410_411dup | 0/0              | 0/1                | 0        |
| NR1D1                        | structural_interaction | c.1318T>G      | -            | 0/0              | 0/1                | 0        |
|                              | missense               | c.1576A>C      | p.Lys526Gln  | 0/0              | 0/1                | 0        |
|                              | inframe_insertion      | c.252_260dup   | p.85_87dup   | 0/0              | 0/1                | 0        |
|                              | missense               | c.1075C>T      | p.Arg359Cys  | 0/0              | 0/2                | 6.20E-04 |
|                              | protein contact        | c.1332G>A      | -            | 0/0              | 0/0                | 3.10E-04 |
|                              | inframe_insertion      | c.324_326dup   | p.Glu108dup  | 0/1              | 0/3                | 3.10E-04 |
| RORA                         | missense               | c.109C>T       | p.Arg37Cys   | 0/1              | 0/0                | 3.10E-04 |
| ARNTL2                       | no variant             | -              | -            | -                | -                  | -        |

\*Affected: DSPD and/or ADHD; Unaffected: No DSPD or ADHD; MAF-TR: Minor allele frequency of the variant in in-house cohort.

62  
63



64 **Supplemental Table 18.** Oligonucleotide primers used in the cloning of *CRY1*.

|                     |               |  |
|---------------------|---------------|--|
| pMU2                | XbaI_hCRY1_F  | 5'gcattctagaatgggggtgaacccgtgc3'             |
|                     | NotI_hCRY1_R  | 5'gcacgcccgttaattagtctctgtctctggacttaggacc3' |
| pcDNA4/<br>myc-HisA | EcoRV_hCRY1_F | 5'gcgatatcatgggggtgaacccgtgc3'               |
|                     | NotI_hCRY1_R  | 5'gcacgcccgcgacttagtctctgtctctggacttaggacc3' |

65 **Supplemental Table 19.** Oligonucleotide primers used in the mutagenesis of *CRY1*.

|                         |                    |  |
|-------------------------|--------------------|--|
| <b>Exon 6 Deletion</b>  | hCRY1_del-exon6_F  | ggaaagaaaagtaagaagaacagtccccctccc      |
|                         | hCRY1_del-exon6_R  | tcttcttacttttcttccaatgccttccaacgagtaag |
| <b>Exon 11 Deletion</b> | hCRY1_del-exon11_F | agcagtgaagaagaagctccatgggcactggtc      |
|                         | hCRY1_del-exon11_R | gagcttcttctcactgctgtctacaacctggg       |

66

67 **Supplemental Table 20.** Reaction conditions for Phusion polymerase amplification.

|                                   | <b>Volume</b>               | <b>Final Concentration</b> |
|-----------------------------------|-----------------------------|----------------------------|
| 5X Phusion HF Buffer              | 10 $\mu$ l                  | 1X                         |
| 10 mM dNTP Mix                    | 1.0 $\mu$ l                 | 200 $\mu$ M                |
| 10 $\mu$ M Forward Primer         | 2.5 $\mu$ l                 | 0.5 $\mu$ M                |
| 10 $\mu$ M Reverse Primer         | 2.5 $\mu$ l                 | 0.5 $\mu$ M                |
| 100% DMSO                         | 1.5 $\mu$ l                 | 3%                         |
| cDNA Template                     | 2.0 $\mu$ l                 |                            |
| Phusion Polymerase (2 U/ $\mu$ l) | 0.5 $\mu$ l                 | 1 U                        |
| ddH <sub>2</sub> O                | 30 $\mu$ l                  |                            |
| <b>Total</b>                      | <b>50 <math>\mu</math>l</b> |                            |

68 **Supplemental Table 21.** Cycling conditions for touchdown PCR.

|                      | <b>Temperature</b> | <b>Time</b> | <b>Cycles</b> |
|----------------------|--------------------|-------------|---------------|
| Initial Denaturation | 98 °C              | 2 min       |               |
| Denaturation         | 98 °C              | 20 sec      | 12 cycles     |
| Annealing            | 72 °C – 1 °C/cycle | 30 sec      |               |
| Elongation           | 72 °C              | 45 sec      |               |
| Denaturation         | 98 °C              | 20 sec      | 23 cycles     |
| Annealing            | 60 °C              | 30 sec      |               |
| Elongation           | 72 °C              | 45 sec      |               |
| Final Elongation     | 72 °C              | 5 min       |               |

69 **Supplemental Table 22.** Reaction conditions for Phusion polymerase amplification.

|                                   | <b>Volume</b>              | <b>Final Concentration</b> |
|-----------------------------------|----------------------------|----------------------------|
| 5X Phusion HF Buffer              | 10 $\mu$ l                 | 1X                         |
| 10 mM dNTP Mix                    | 1.0 $\mu$ l                | 200 $\mu$ M                |
| 10 $\mu$ M Forward Primer         | 1.0 $\mu$ l                | 0.2 $\mu$ M                |
| 10 $\mu$ M Reverse Primer         | 1.0 $\mu$ l                | 0.2 $\mu$ M                |
| 100% DMSO                         | 1.5 $\mu$ l                | 3%                         |
| Plasmid Template (50 ng/ $\mu$ l) | 0.5 $\mu$ l                | 25 ng                      |
| Phusion Polymerase (2 U/ $\mu$ l) | 0.5 $\mu$ l                | 1 U                        |
| ddH <sub>2</sub> O                | 34.5 $\mu$ l               |                            |
| <b>Total</b>                      | <b>50<math>\mu</math>l</b> |                            |

70 **Supplemental Table 23.** Cycling conditions for touchdown PCR.

|                      | <b>Temperature</b> | <b>Time</b>  | <b>Cycles</b> |
|----------------------|--------------------|--------------|---------------|
| Initial Denaturation | 98 °C              | 2 min        |               |
| Denaturation         | 98 °C              | 20 sec       | 20 cycles     |
| Annealing            | 64 °C              | 30 sec       |               |
| Elongation           | 72 °C              | 3 min 30 sec |               |
| Final Elongation     | 72 °C              | 5 min        |               |

71

72 **Supplemental Table 24. Statistics**

|  | <b>Carrier</b> | <b>Non-carrier</b> | <b><i>P</i></b>          | <b>OR</b> | <b>95% CI</b> |
|--|----------------|--------------------|--------------------------|-----------|---------------|
| <b>14-families from Turkey and Italy</b> |                |                    |                          |           |               |
| <b>ADHD phenotype</b>                    |                |                    |                          |           |               |
| Affected                                 | 51             | 4                  | 1.99 x 10 <sup>-21</sup> | 280.5     | 49-1,606      |
| Not-affected                             | 2              | 44                 |                          |           |               |
| <b>Depression</b>                        |                |                    |                          |           |               |
| Affected                                 | 34             | 5                  | 1.65 x 10 <sup>-8</sup>  | 15.4      | 5.21-45.4     |
| Not-affected                             | 19             | 43                 |                          |           |               |
| <b>447-individual validation cohort</b>  |                |                    |                          |           |               |
| <b>ADHD phenotype</b>                    |                |                    |                          |           |               |
| Affected                                 | 9              | 69                 | 8.64 x 10 <sup>-7</sup>  | 48.0      | 5.98-384      |
| Not-affected                             | 1              | 368                |                          |           |               |
| <b>DSPD phenotype</b>                    |                |                    |                          |           |               |
| Affected                                 | 10             | 175                | 1.2 x 10 <sup>-4</sup>   | 31.4      | 1.83-539      |
| Not-affected                             | 0              | 262                |                          |           |               |

73